Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Regeneron Pharmaceuticals, Inc. (REGN) since 2005 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Regeneron Pharmaceuticals, Inc.. (See page 1 of this report.) Table 2 shows the detailed insider transactions. This company's CIK number is 872589.
Total stock buying since 2005: $2,475,753,844.
Total stock sales since 2005: $14,586,084,237.
Total stock option exercises since 2005: $1,313,104,322.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2024 | 0 | $0 | 210,364 | $207,522,474 | 616,322 | $254,112,622 |
| 2023 | 0 | $0 | 95,808 | $78,349,729 | 273,334 | $75,352,970 |
| 2022 | 0 | $0 | 209,705 | $142,182,035 | 469,330 | $145,352,340 |
| 2021 | 0 | $0 | 563,365 | $351,623,746 | 2,003,096 | $333,732,044 |
| 2020 | 0 | $0 | 24,311,062 | $12,445,396,750 | 1,955,372 | $164,839,706 |
| 2019 | 0 | $0 | 416,206 | $143,310,975 | 917,671 | $23,311,139 |
| 2018 | 0 | $0 | 427,003 | $148,810,340 | 927,576 | $18,552,974 |
| 2017 | 462,141 | $212,021,764 | 137,384 | $65,407,790 | 900,886 | $27,301,249 |
| 2016 | 148,669 | $62,482,433 | 20,663 | $8,394,544 | 774,368 | $17,691,794 |
| 2015 | 260,466 | $131,463,987 | 420,930 | $219,457,542 | 678,280 | $37,168,578 |
| 2014 | 6,498,829 | $2,040,580,495 | 592,551 | $211,494,397 | 1,689,378 | $74,072,416 |
| 2013 | 0 | $0 | 979,452 | $254,768,275 | 1,464,593 | $33,265,521 |
| 2012 | 0 | $0 | 1,215,019 | $159,380,088 | 2,319,093 | $46,475,631 |
| 2011 | 0 | $0 | 729,476 | $37,856,945 | 1,678,597 | $36,895,258 |
| 2010 | 1,034,901 | $28,971,078 | 317,918 | $9,118,977 | 332,278 | $5,014,862 |
| 2009 | 12,500 | $234,087 | 114,271 | $2,249,950 | 651,002 | $5,760,483 |
| 2008 | 0 | $0 | 156,479 | $3,272,738 | 500,195 | $4,022,051 |
| 2007 | 0 | $0 | 224,867 | $5,157,435 | 316,441 | $3,033,949 |
| 2006 | 0 | $0 | 443,650 | $8,648,660 | 580,125 | $5,427,485 |
| 2005 | 0 | $0 | 7,562,667 | $83,680,847 | 135,000 | $1,721,250 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2012-11-16 | Schleifer Leonard S (President & CEO) | Option Ex | 43,757 | 111.01 | 4,857,464 |
| 2012-11-14 | Goldberg Murray A (SVP Finance and Admin CFO Trea) | Sale | 3,156 | 148.49 | 468,643 |
| 2012-11-14 | Brown Michael S (Director) | Sale | 7,000 | 147.03 | 1,029,210 |
| 2012-11-14 | Brown Michael S (Director) | Option Ex | 7,000 | 23.84 | 166,880 |
| 2012-11-13 | Goldberg Murray A (SVP Finance and Admin CFO Trea) | Sale | 6,537 | 146.45 | 957,356 |
| 2012-11-13 | Goldberg Murray A (SVP Finance and Admin CFO Trea) | Option Ex | 8,176 | 37.13 | 303,574 |
| 2012-11-13 | Sing George L (Director) | Sale | 5,000 | 148.00 | 740,000 |
| 2012-11-08 | Powchik Peter (SVP Clinical Development & Reg) | Sale | 15,144 | 138.82 | 2,102,290 |
| 2012-11-01 | Ryan Arthur F (Director) | Sale | 10,000 | 145.57 | 1,455,700 |
| 2012-10-26 | Brown Michael S (Director) | Sale | 3,000 | 154.69 | 464,070 |
| 2012-10-26 | Brown Michael S (Director) | Option Ex | 3,000 | 23.84 | 71,520 |
| 2012-10-25 | Van Plew Daniel P (SVP & General Mgr Industrial O) | Option Ex | 30,000 | 21.92 | 657,600 |
| 2012-10-25 | Brown Michael S (Director) | Sale | 2,000 | 155.34 | 310,680 |
| 2012-10-25 | Brown Michael S (Director) | Option Ex | 2,000 | 23.84 | 47,680 |
| 2012-09-19 | Powchik Peter (SVP Clinical Development & Reg) | Sale | 7,177 | 147.35 | 1,057,530 |
| 2012-09-18 | Powchik Peter (SVP Clinical Development & Reg) | Option Ex | 15,000 | 16.80 | 252,000 |
| 2012-09-06 | Baker Charles A (Director) | Sale | 13,714 | 150.00 | 2,057,100 |
| 2012-09-06 | Baker Charles A (Director) | Option Ex | 13,714 | 15.01 | 205,847 |
| 2012-09-05 | Baker Charles A (Director) | Sale | 1,286 | 150.00 | 192,900 |
| 2012-09-05 | Baker Charles A (Director) | Option Ex | 1,286 | 15.01 | 19,302 |
| 2012-08-31 | Goldberg Murray A (SVP Finance and Admin CFO Trea) | Sale | 5,296 | 145.94 | 772,914 |
| 2012-08-29 | Stahl Neil (SVP Research and Development S) | Sale | 16,884 | 145.59 | 2,458,141 |
| 2012-08-28 | Stahl Neil (SVP Research and Development S) | Option Ex | 40,000 | 21.92 | 876,800 |
| 2012-08-24 | Mccorkle Douglas S (VP Controller and Asst Treasur) | Sale | 6,727 | 144.67 | 973,181 |
| 2012-08-23 | Mccorkle Douglas S (VP Controller and Asst Treasur) | Option Ex | 15,125 | 25.94 | 392,342 |
| 2012-08-23 | Roberts William (VP Regulatory Development and) | Sale | 15,000 | 144.00 | 2,160,000 |
| 2012-08-23 | Sing George L (Director) | Sale | 5,000 | 142.00 | 710,000 |
| 2012-08-23 | Sing George L (Director) | Option Ex | 5,000 | 18.80 | 94,000 |
| 2012-08-22 | Sing George L (Director) | Sale | 5,000 | 139.00 | 695,000 |
| 2012-08-22 | Sing George L (Director) | Option Ex | 5,000 | 18.80 | 94,000 |
| 2012-08-10 | Ryan Arthur F (Director) | Sale | 10,000 | 136.15 | 1,361,500 |
| 2012-08-07 | Gilman Alfred G (Director) | Sale | 15,000 | 139.56 | 2,093,400 |
| 2012-08-07 | Gilman Alfred G (Director) | Option Ex | 15,000 | 15.80 | 237,000 |
| 2012-08-06 | Brown Michael S (Director) | Sale | 3,000 | 136.29 | 408,870 |
| 2012-08-06 | Brown Michael S (Director) | Option Ex | 3,000 | 23.84 | 71,520 |
| 2012-08-01 | Powchik Peter (SVP Clinical Development & Reg) | Option Ex | 14,990 | 18.78 | 281,512 |
| 2012-07-30 | Terifay Robert J (SVP Commercial) | Sale | 23,834 | 136.08 | 3,243,330 |
| 2012-07-27 | Terifay Robert J (SVP Commercial) | Option Ex | 50,875 | 18.51 | 941,543 |
| 2012-07-26 | Powchik Peter (SVP Clinical Development & Reg) | Sale | 7,019 | 130.74 | 917,628 |
| 2012-07-26 | Sing George L (Director) | Sale | 5,000 | 135.00 | 675,000 |
| 2012-07-26 | Sing George L (Director) | Option Ex | 5,000 | 18.80 | 94,000 |
| 2012-07-25 | Powchik Peter (SVP Clinical Development & Reg) | Option Ex | 15,000 | 16.80 | 252,000 |
| 2012-06-19 | Stahl Neil (SVP Res & Dev Sciences) | Sale | 38,911 | 116.86 | 4,547,256 |
| 2012-06-18 | Stahl Neil (SVP Res & Dev Sciences) | Option Ex | 95,079 | 20.32 | 1,932,005 |
| 2012-05-31 | Sing George L (Director) | Sale | 5,000 | 134.94 | 674,725 |
| 2012-05-30 | Sing George L (Director) | Sale | 5,000 | 134.00 | 670,000 |
| 2012-05-24 | Aberman Michael S (VP Strategy and Investor Relat) | Option Ex | 500 | 24.00 | 12,000 |
| 2012-05-21 | Goldberg Murray A (SVP Finance and Admin CFO Trea) | Option Ex | 16,244 | 16.78 | 272,574 |
| 2012-05-21 | Shooter Eric M (Director) | Sale | 18,000 | 123.65 | 2,225,700 |
| 2012-05-21 | Shooter Eric M (Director) | Option Ex | 18,000 | 21.51 | 387,180 |
| 2012-05-18 | Shooter Eric M (Director) | Sale | 2,000 | 124.04 | 248,080 |
| 2012-05-18 | Shooter Eric M (Director) | Option Ex | 2,000 | 18.61 | 37,220 |
| 2012-05-03 | Goldberg Murray A (SVP Finance and Admin CFO Trea) | Sale | 24,642 | 135.51 | 3,339,163 |
| 2012-05-02 | Goldberg Murray A (SVP Finance and Admin CFO Trea) | Sale | 6,945 | 136.48 | 947,853 |
| 2012-05-02 | Goldberg Murray A (SVP Finance and Admin CFO Trea) | Option Ex | 54,438 | 21.92 | 1,193,280 |
| 2012-05-01 | Aberman Michael S (VP Strategy and Investor Relat) | Sale | 6,162 | 134.91 | 831,284 |
| 2012-05-01 | Yancopoulos George (EVP CSO President Regeneron Re) | Sale | 33,165 | 134.59 | 4,463,776 |
| 2012-05-01 | Schleifer Leonard S (President & CEO) | Sale | 100,000 | 135.07 | 13,506,800 |
| 2012-04-30 | Aberman Michael S (VP Strategy and Investor Relat) | Option Ex | 12,500 | 24.00 | 300,000 |
| 2012-04-30 | Van Plew Daniel P (SVP & General Mgr Industrial O) | Sale | 14,442 | 136.18 | 1,966,711 |
| 2012-04-27 | Van Plew Daniel P (SVP & General Mgr Industrial O) | Option Ex | 35,216 | 20.90 | 736,014 |
| 2012-04-19 | Baker Charles A (Director) | Sale | 12,910 | 125.00 | 1,613,750 |
| 2012-04-19 | Baker Charles A (Director) | Option Ex | 12,910 | 18.80 | 242,708 |
| 2012-04-17 | Baker Charles A (Director) | Sale | 2,090 | 125.00 | 261,250 |
| 2012-04-17 | Baker Charles A (Director) | Option Ex | 2,090 | 18.80 | 39,292 |
| 2012-03-26 | Yancopoulos George (EVP CSO President Regeneron Re) | Sale | 33,150 | 120.65 | 3,999,547 |
| 2012-03-26 | Goldstein Joseph L (Director) | Sale | 5,000 | 120.00 | 600,000 |
| 2012-03-26 | Goldstein Joseph L (Director) | Option Ex | 5,000 | 18.61 | 93,050 |
| 2012-03-15 | Goldstein Joseph L (Director) | Sale | 10,000 | 112.28 | 1,122,770 |
| 2012-03-15 | Goldstein Joseph L (Director) | Option Ex | 10,000 | 18.61 | 186,100 |
| 2012-03-01 | Brown Michael S (Director) | Sale | 20,000 | 103.29 | 2,065,720 |
| 2012-03-01 | Brown Michael S (Director) | Option Ex | 20,000 | 18.91 | 378,240 |
| 2012-02-23 | Shooter Eric M (Director) | Sale | 20,000 | 103.78 | 2,075,600 |
| 2012-02-22 | Powchik Peter (SVP Clinical Development & Reg) | Sale | 49,254 | 96.45 | 4,750,548 |
| 2012-02-21 | Powchik Peter (SVP Clinical Development & Reg) | Option Ex | 109,866 | 18.67 | 2,051,198 |
| 2012-02-16 | Mccorkle Douglas S (VP Controller and Asst Treasur) | Sale | 5,353 | 107.50 | 575,447 |
| 2012-02-15 | Mccorkle Douglas S (VP Controller and Asst Treasur) | Sale | 9,097 | 111.08 | 1,010,494 |
| 2012-02-15 | Yancopoulos George (EVP CSO President Regeneron Re) | Option Ex | 133,332 | 8.50 | 1,133,322 |
| 2012-02-15 | Stahl Neil (SVP Research and Development S) | Sale | 21,082 | 107.94 | 2,275,591 |
| 2012-02-15 | Gilman Alfred G (Director) | Sale | 26,734 | 109.56 | 2,928,977 |
| 2012-02-14 | Mccorkle Douglas S (VP Controller and Asst Treasur) | Sale | 4,562 | 109.75 | 500,702 |
| 2012-02-14 | Mccorkle Douglas S (VP Controller and Asst Treasur) | Option Ex | 35,000 | 20.64 | 722,400 |
| 2012-02-14 | Stahl Neil (SVP Research and Development S) | Sale | 31,202 | 110.55 | 3,449,474 |
| 2012-02-14 | Stahl Neil (SVP Research and Development S) | Option Ex | 50,000 | 16.80 | 840,000 |
| 2012-02-14 | Goldstein Joseph L (Director) | Sale | 15,000 | 110.02 | 1,650,300 |
| 2012-02-14 | Goldstein Joseph L (Director) | Option Ex | 15,000 | 28.91 | 433,725 |
| 2012-02-14 | Gilman Alfred G (Director) | Option Ex | 30,000 | 12.09 | 362,700 |
| 2012-02-14 | Schleifer Leonard S (President & CEO) | Option Ex | 500,000 | 15.14 | 7,571,500 |
| 2012-02-13 | Stahl Neil (SVP Research and Development S) | Option Ex | 66,666 | 8.50 | 566,661 |
| 2012-02-07 | Goldberg Murray A (SVP Finance and Admin CFO Trea) | Sale | 17,500 | 100.48 | 1,758,400 |
| 2012-02-06 | Goldberg Murray A (SVP Finance and Admin CFO Trea) | Option Ex | 40,913 | 20.97 | 857,945 |
| 2012-02-01 | Terifay Robert J (SVP Commercial) | Sale | 9,439 | 90.79 | 856,966 |
| 2012-02-01 | Goldberg Murray A (SVP Finance and Admin CFO Trea) | Sale | 18,258 | 91.90 | 1,677,964 |
| 2012-01-31 | Terifay Robert J (SVP Commercial) | Option Ex | 23,128 | 21.92 | 506,965 |
| 2012-01-31 | Goldberg Murray A (SVP Finance and Admin CFO Trea) | Option Ex | 44,079 | 21.12 | 930,948 |
| 2012-01-20 | Goldberg Murray A (SVP Finance and Admin CFO Trea) | Sale | 17,183 | 78.51 | 1,349,088 |
| 2012-01-19 | Goldberg Murray A (SVP Finance and Admin CFO Trea) | Option Ex | 40,800 | 20.32 | 829,056 |
| 2012-01-19 | Goldstein Joseph L (Director) | Sale | 10,000 | 80.00 | 800,000 |
| 2012-01-12 | Ryan Arthur F (Director) | Sale | 25,500 | 78.97 | 2,013,862 |
| 2012-01-11 | Terifay Robert J (SVP Commercial) | Sale | 9,019 | 74.20 | 669,209 |
| 2012-01-11 | Roberts William (VP Regulatory Development and) | Sale | 22,148 | 75.49 | 1,672,041 |
| 2012-01-10 | Terifay Robert J (SVP Commercial) | Option Ex | 20,000 | 21.63 | 432,600 |
| 2012-01-10 | Roberts William (VP Regulatory Development and) | Sale | 9,528 | 74.35 | 708,406 |
| 2012-01-10 | Roberts William (VP Regulatory Development and) | Option Ex | 60,000 | 21.12 | 1,267,200 |
| 2012-01-10 | Goldstein Joseph L (Director) | Sale | 20,000 | 74.57 | 1,491,339 |
| 2012-01-10 | Goldstein Joseph L (Director) | Option Ex | 20,000 | 21.07 | 421,460 |
| 2012-01-05 | Yancopoulos George (EVP, CSO & Pres, REGN Res Labs) | Sale | 27,713 | 58.00 | 1,607,354 |
| 2011-12-20 | Goldberg Murray A (SVP Finance and Admin CFO Trea) | Option Ex | 2,500 | 11.64 | 29,100 |
| 2011-12-16 | Schleifer Leonard S (President & CEO) | Option Ex | 250,000 | 28.01 | 7,002,500 |
| 2011-12-01 | Yancopoulos George (EVP CSO President Regeneron Re) | Sale | 27,713 | 59.16 | 1,639,362 |
| 2011-11-30 | Yancopoulos George (EVP CSO President Regeneron Re) | Option Ex | 200,000 | 28.01 | 5,602,000 |
| 2011-11-22 | Sing George L (Director) | Option Ex | 15,000 | 28.81 | 432,150 |
| 2011-11-14 | Stahl Neil (SVP Research and Development S) | Option Ex | 17,182 | 11.64 | 199,998 |
| 2011-10-14 | Goldstein Joseph L (Director) | Sale | 10,000 | 65.00 | 650,000 |
| 2011-10-14 | Goldstein Joseph L (Director) | Option Ex | 10,000 | 23.84 | 238,400 |
| 2011-10-11 | Terifay Robert J (SVP Commercial) | Sale | 7,214 | 65.16 | 470,064 |
| 2011-10-10 | Terifay Robert J (SVP Commercial) | Option Ex | 29,372 | 21.34 | 626,798 |
| 2011-10-04 | Goldberg Murray A (SVP Finance and Admin CFO Trea) | Option Ex | 13,749 | 11.38 | 156,422 |
| 2011-09-21 | Goldberg Murray A (SVP Finance and Admin CFO Trea) | Sale | 4,200 | 67.00 | 281,400 |
| 2011-09-21 | Brown Michael S (Director) | Sale | 5,000 | 78.00 | 390,000 |
| 2011-09-21 | Brown Michael S (Director) | Option Ex | 5,000 | 9.17 | 45,850 |
| 2011-09-14 | Ryan Arthur F (Director) | Option Ex | 115,000 | 18.44 | 2,120,370 |
| 2011-09-09 | Goldberg Murray A (SVP Finance and Admin CFO Trea) | Sale | 7,542 | 68.24 | 514,666 |
| 2011-09-08 | Goldberg Murray A (SVP Finance and Admin CFO Trea) | Option Ex | 26,000 | 11.64 | 302,640 |
| 2011-09-08 | Brown Michael S (Director) | Sale | 5,000 | 74.00 | 370,000 |
| 2011-09-08 | Brown Michael S (Director) | Option Ex | 5,000 | 9.17 | 45,850 |
| 2011-09-07 | Aberman Michael S (VP Strategy and Investor Relat) | Sale | 3,377 | 69.04 | 233,137 |
| 2011-09-07 | Stahl Neil (SVP Research and Development S) | Sale | 33,760 | 69.06 | 2,331,296 |
| 2011-09-07 | Roberts William (VP Regulatory Development and) | Sale | 6,503 | 69.06 | 449,129 |
| 2011-09-07 | Goldberg Murray A (SVP Finance and Admin CFO Trea) | Sale | 13,531 | 69.06 | 934,518 |
| 2011-09-07 | Brown Michael S (Director) | Sale | 5,000 | 69.00 | 345,000 |
| 2011-09-07 | Brown Michael S (Director) | Option Ex | 5,000 | 9.17 | 45,850 |
| 2011-09-06 | Aberman Michael S (VP Strategy and Investor Relat) | Option Ex | 8,334 | 24.00 | 200,016 |
| 2011-09-06 | Stahl Neil (SVP Research and Development S) | Option Ex | 82,818 | 11.64 | 964,001 |
| 2011-09-06 | Roberts William (VP Regulatory Development and) | Sale | 16,463 | 65.54 | 1,078,985 |
| 2011-09-06 | Roberts William (VP Regulatory Development and) | Option Ex | 30,000 | 11.64 | 349,200 |
| 2011-09-06 | Goldberg Murray A (SVP Finance and Admin CFO Trea) | Option Ex | 32,879 | 15.54 | 510,775 |
| 2011-09-06 | Schleifer Leonard S (CEO & President) | Sale | 7,900 | 66.10 | 522,213 |
| 2011-09-02 | Aberman Michael S (VP Strategy and Investor Relat) | Sale | 4,166 | 64.00 | 266,624 |
| 2011-09-02 | Aberman Michael S (VP Strategy and Investor Relat) | Option Ex | 4,166 | 24.00 | 99,984 |
| 2011-09-02 | Vagelos P Roy (Chairman of the Board) | Sale | 88,955 | 61.27 | 5,450,272 |
| 2011-09-01 | Vagelos P Roy (Chairman of the Board) | Sale | 3,500 | 60.00 | 210,000 |
| 2011-08-31 | Vagelos P Roy (Chairman of the Board) | Option Ex | 312,500 | 28.01 | 8,753,125 |
| 2011-08-16 | Goldberg Murray A (SVP Finance and Admin CFO Trea) | Sale | 6,409 | 56.86 | 364,415 |
| 2011-08-15 | Goldberg Murray A (SVP Finance and Admin CFO Trea) | Option Ex | 15,000 | 11.64 | 174,600 |
| 2011-08-10 | Baker Charles A (Director) | Option Ex | 4,000 | 28.81 | 115,240 |
| 2011-08-04 | Van Plew Daniel P (SVP & General Mgr Industrial O) | Option Ex | 4,784 | 20.90 | 99,985 |
| 2011-07-28 | Goldberg Murray A (SVP Finance and Admin CFO Trea) | Sale | 9,705 | 54.48 | 528,689 |
| 2011-07-27 | Goldberg Murray A (SVP Finance and Admin CFO Trea) | Option Ex | 21,963 | 9.49 | 208,428 |
| 2011-07-26 | Powchik Peter (SVP Clinical Development) | Sale | 10,977 | 54.97 | 603,350 |
Insider trading activities including stock purchases, stock sales, and option exercises of REGN listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Regeneron Pharmaceuticals, Inc. (symbol REGN, CIK number 872589) see the Securities and Exchange Commission (SEC) website.